Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613’s Potential Impact

September 2022 – – Entera Bio hosted a key opinion leader (KOL) webinar on the company’s lead asset EB613, and its potential impact on the osteoporosis market. The webinar featured presentations from KOLs John P. Bilezikian, MD, PhD, from Columbia University, Felicia Cosman, MD, also from Columbia University, and Bart L. Clarke, MD, from Mayo Clinic. The event provided insight into the current treatment landscape and unmet medical need for post-menopausal women with osteoporosis. The discussion focused on Entera Bio’s development of EB613, a proprietary formulation of PTH (1-34, teriparatide) as the first potential orally administered osteoanabolic treatment. Entera leadership will review their Phase 2 EB613 data, which will be followed by an overview of the Company’s proposed registrational Phase 3 plan submitted to FDA.

Join event


Entera Bio Announces FDA’s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis

Entera Bio to Participate in the SVB Securities Global Biopharma

Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis

Thank You

Message Sent!

We will get back to you soon